JP7437317B2 - コネキシン43抗体およびその使用 - Google Patents

コネキシン43抗体およびその使用 Download PDF

Info

Publication number
JP7437317B2
JP7437317B2 JP2020554864A JP2020554864A JP7437317B2 JP 7437317 B2 JP7437317 B2 JP 7437317B2 JP 2020554864 A JP2020554864 A JP 2020554864A JP 2020554864 A JP2020554864 A JP 2020554864A JP 7437317 B2 JP7437317 B2 JP 7437317B2
Authority
JP
Japan
Prior art keywords
antibody
binding
antibodies
antigen
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020554864A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021520393A5 (cg-RX-API-DMAC7.html
JP2021520393A (ja
Inventor
ヤンフェン ジャン,
Original Assignee
アラマブ セラピューティクス, インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アラマブ セラピューティクス, インコーポレイテッド filed Critical アラマブ セラピューティクス, インコーポレイテッド
Publication of JP2021520393A publication Critical patent/JP2021520393A/ja
Publication of JP2021520393A5 publication Critical patent/JP2021520393A5/ja
Priority to JP2024018521A priority Critical patent/JP7829605B2/ja
Application granted granted Critical
Publication of JP7437317B2 publication Critical patent/JP7437317B2/ja
Priority to JP2026033506A priority patent/JP2026090576A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2020554864A 2018-04-02 2019-04-02 コネキシン43抗体およびその使用 Active JP7437317B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024018521A JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用
JP2026033506A JP2026090576A (ja) 2018-04-02 2026-03-03 コネキシン43抗体およびその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862651668P 2018-04-02 2018-04-02
US62/651,668 2018-04-02
PCT/US2019/025363 WO2019195273A1 (en) 2018-04-02 2019-04-02 Connexin 43 antibodies and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024018521A Division JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用

Publications (3)

Publication Number Publication Date
JP2021520393A JP2021520393A (ja) 2021-08-19
JP2021520393A5 JP2021520393A5 (cg-RX-API-DMAC7.html) 2022-04-11
JP7437317B2 true JP7437317B2 (ja) 2024-02-22

Family

ID=68101187

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020554864A Active JP7437317B2 (ja) 2018-04-02 2019-04-02 コネキシン43抗体およびその使用
JP2024018521A Active JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用
JP2026033506A Pending JP2026090576A (ja) 2018-04-02 2026-03-03 コネキシン43抗体およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024018521A Active JP7829605B2 (ja) 2018-04-02 2024-02-09 コネキシン43抗体およびその使用
JP2026033506A Pending JP2026090576A (ja) 2018-04-02 2026-03-03 コネキシン43抗体およびその使用

Country Status (6)

Country Link
US (2) US12227561B2 (cg-RX-API-DMAC7.html)
JP (3) JP7437317B2 (cg-RX-API-DMAC7.html)
CN (2) CN116854816A (cg-RX-API-DMAC7.html)
AU (2) AU2019249427B2 (cg-RX-API-DMAC7.html)
CA (1) CA3095897A1 (cg-RX-API-DMAC7.html)
WO (1) WO2019195273A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
AU2020219112A1 (en) * 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CA3131925A1 (en) * 2019-02-28 2020-09-03 Board Of Regents, The University Of Texas System Compositions for treating osteosarcoma and methods of use
CA3156812A1 (en) 2019-10-02 2021-04-08 Alamab Therapeutics, Inc. Anti-connexin antibody formulations
CN113307871B (zh) * 2020-02-27 2023-05-02 福州拓新天成生物科技有限公司 新型抗cd19抗体和cd19-car-t细胞的制备及其应用
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations
AU2024276084A1 (en) * 2023-05-24 2025-12-18 Alamab Therapeutics, Inc. Method of treating bone cancers
US12571255B2 (en) 2023-06-02 2026-03-10 Universal Electronics Inc. Systems and method for controlling window treatments

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
AU2002362197A1 (en) 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
PT2418220T (pt) 2003-12-10 2017-10-04 Squibb & Sons Llc Anticorpos contra interferão alfa e suas utilizações
CN101573131B (zh) 2005-02-03 2017-12-01 科达治疗有限公司 抗‑连接蛋白化合物及其治疗应用
AU2009246640A1 (en) 2008-05-15 2009-11-19 Biogen Idec Ma Inc. Anti-Fn14 antibodies and uses thereof
WO2009148613A1 (en) 2008-06-04 2009-12-10 Coda Therapeutics, Inc. Treatment of pain with gap junction modulation compounds
US8956868B2 (en) 2010-12-27 2015-02-17 Lsip, Llc Induced pluripotent stem cells produced with a connexin inhibitor and a TGF-β signaling inhibitor
WO2015027120A1 (en) 2013-08-21 2015-02-26 Jiang Jean X Compositions and methods for targeting connexin hemichannels
US9493552B2 (en) 2013-11-15 2016-11-15 China Synthetic Rubber Corporation Therapeutic biologic for treatment of hepatocellular carcinoma
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CN116854816A (zh) 2018-04-02 2023-10-10 阿拉玛布治疗学股份有限公司 连接蛋白43抗体及其用途
AU2020219112A1 (en) 2019-02-04 2021-08-26 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
IL300245A (en) * 2020-07-31 2023-03-01 Alamab Therapeutics Inc Anti-connexin antibody formulations

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017147561A1 (en) 2016-02-26 2017-08-31 The Board Of Regents Of The University Of Texas System CONNEXIN (Cx) 43 HEMICHANNEL-BINDING ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
JP2026090576A (ja) 2026-06-02
US12227561B2 (en) 2025-02-18
JP2021520393A (ja) 2021-08-19
US20210163581A1 (en) 2021-06-03
US20250289876A1 (en) 2025-09-18
JP7829605B2 (ja) 2026-03-13
CN116854816A (zh) 2023-10-10
JP2024042116A (ja) 2024-03-27
WO2019195273A1 (en) 2019-10-10
CN112368299A (zh) 2021-02-12
AU2026202530A1 (en) 2026-05-21
AU2019249427B2 (en) 2026-01-08
EP3774891A1 (en) 2021-02-17
AU2019249427A1 (en) 2020-10-29
CA3095897A1 (en) 2019-10-10

Similar Documents

Publication Publication Date Title
JP7829605B2 (ja) コネキシン43抗体およびその使用
CA2741127C (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
JP5908972B2 (ja) 新規な抗原結合タンパク質
CN109071646A (zh) TGFβ1-结合免疫球蛋白及其用途
US20250230233A1 (en) Connexin 43 antibodies and use thereof
KR102428255B1 (ko) 위암의 검출 및 치료를 위한 조성물 및 방법
KR20250143315A (ko) 항-vegfa 및 vegfc 이중특이적 결합 단백질을 포함하는 약제학적 제제
HK40100613A (en) Connexin 43 antibodies and use thereof
HK40042791A (en) Connexin 43 antibodies and use thereof
TWI901797B (zh) 抗-sema3a抗體及其用於治療視網膜栓塞疾病之用途
HK40043616A (en) Connexin 43 antibodies and use thereof
HK40043616B (en) Connexin 43 antibodies and use thereof
BR112020010336A2 (pt) composições e métodos para terapia de câncer
HK1248122A1 (zh) 抗met抗體及其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230308

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230817

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240111

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240209

R150 Certificate of patent or registration of utility model

Ref document number: 7437317

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150